Active, not recruitingNCT05568459
A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy
Studying Hemophilia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Regeneron Pharmaceuticals
- Principal Investigator
- Clinical Trial ManagementRegeneron Pharmaceuticals
- Intervention
- Non-Interventional(other)
- Enrollment
- 11 enrolled
- Eligibility
- 16 years · MALE
- Timeline
- 2024 – 2026
Study locations (17)
- University of Colorado Hemophilia and Thrombosis Center, Aurora, Colorado, United States
- Yale HTC, New Haven, Connecticut, United States
- Georgetown University Medical Center, Washington D.C., District of Columbia, United States
- University of Florida, Gainesville, Florida, United States
- Rush University Medical Center, Chicago, Illinois, United States
- Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- University of Texas Health Science Center at Houston, Houston, Texas, United States
- McMaster University Medical Centre - Hamilton Health Sciences, Hamilton, Ontario, Canada
- Mcgill University Health Center (MUHC), Montreal, Quebec, Canada
- University Hospital of Regensburg, Regensburg, Bavaria, Germany
- Klinikum der Johann Wolfgang Goethe-Universitaet Frankfurt, Frankfurt, Germany
- University Hospital Hamburg Eppendorf, Hamburg, Germany
- Southampton General Hospital, Southampton, Hampshire, United Kingdom
- +2 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05568459 on ClinicalTrials.govOther trials for Hemophilia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT07406139PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE3NCT04563520SAFE Study: Safety of aPCC Following Emicizumab ProphylaxisEmory University
- RECRUITINGNCT07101926Monitoring of Anti-TFPI in HemophiliaHospices Civils de Lyon
- RECRUITINGPHASE4NCT06941870Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial HypertrophySanofi
- RECRUITINGNCT07314983Long-term Anticoagulation in a Patient With Severe Hemophilia AUniversity Hospital, Strasbourg, France
- RECRUITINGPHASE4NCT06940830Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog AlfaSwedish Orphan Biovitrum
- RECRUITINGPHASE1NCT06703606A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.Pfizer
- RECRUITINGPHASE3NCT06833983To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia AGritgen Therapeutics Co., Ltd.